论文部分内容阅读
目的探讨微生态制剂对重型肝炎患者自发性细菌性腹膜炎(SBP)的预防效果。方法 104例重型肝炎患者在综合护肝治疗的基础上随机分为3组:A组35例,肠道选择性净化联合微生态制剂;B组37例,单用肠道选择性净化;C组32例,为对照组,两种治疗方法均未使用。对3组患者SBP发生率、平均住院天数、病死率进行对比分析。结果 A、B2个治疗组较对照组SBP发生率明显下降(χ2≥13.64,P<0.05),住院天数显著缩短(t≥2.52,P<0.05),病死率显著降低(χ2≥4.38,P<0.05);在2个治疗组中,A组较B组疗效变化更显著。结论在肠道选择性净化的基础上加用微生态制剂可有效降低重型肝炎的SBP发生率及病死率,缩短住院天数。
Objective To investigate the preventive effect of probiotics on spontaneous bacterial peritonitis (SBP) in patients with severe hepatitis. Methods One hundred and four patients with severe hepatitis were randomly divided into three groups based on the comprehensive hepatoprotective therapy: 35 cases in group A and selective intestinal combined with probiotics; 37 cases in group B, 32 cases as control group, neither of the two treatment methods were used. The incidence of SBP, average days of hospitalization and mortality in three groups were compared. Results The incidences of SBP in the two treatment groups were significantly lower than those in the control group (χ2≥13.64, P <0.05), hospital days significantly shorter (t≥2.52, P <0.05) and mortality was significantly lower (χ2≥4.38, P < 0.05). In the two treatment groups, the change of efficacy in group A was more significant than that in group B. Conclusions The addition of probiotics on the basis of selective intestinal purification can effectively reduce the incidence of SBP and mortality in severe hepatitis and shorten the length of hospital stay.